Mesoblast (NASDAQ:MESO) Trading 9.4% Higher

Mesoblast Limited (NASDAQ:MESO) traded up 9.4% during trading on Tuesday . The company traded as high as $6.10 and last traded at $6.05. 86,065 shares were traded during mid-day trading, a decline of 95% from the average session volume of 1,830,111 shares. The stock had previously closed at $5.53.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a research report on Friday, January 12th. StockNews.com lowered Mesoblast from a “hold” rating to a “sell” rating in a research report on Tuesday, April 2nd. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $13.67.

Mesoblast Price Performance

The company has a 50-day simple moving average of $3.54 and a 200 day simple moving average of $2.66.

Institutional Investors Weigh In On Mesoblast

A hedge fund recently bought a new stake in Mesoblast stock. Prosperity Wealth Management Inc. bought a new stake in shares of Mesoblast Limited (NASDAQ:MESO) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 64,150 shares of the company’s stock, valued at approximately $79,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.